BMO Capital Starts Regulus Therapeutics (RGLS) at Outperform
Tweet
Share
E-mailGet Alerts RGLS Hot Sheet
Price: $8.16 --0%
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 39
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 39
Join SI Premium – FREE
BMO Capital initiates coverage on Regulus Therapeutics (NASDAQ: RGLS) with a Outperform. PT $10.00.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $5.11 yesterday.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $5.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Starts flatexDEGIRO AG (FTKn:GR) (FNNTF) at Overweight
- Bernstein SocGen Group Starts Pepsico (PEP) at Market Perform
- Bernstein SocGen Group Starts Keurig Dr Pepper (KDP) at Outperform, 'outstanding Functional Beverages portfolio'
Create E-mail Alert Related Categories
New CoverageRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
